Senti Biosciences Holdings Inc SNTI 深 沪
已收盘 05-15 16:00:00 美东时间
1.01
-0.030
-2.88%
华盛通- 最 高1.0638
- 今 开1.06
- 成交量 17.21万股
- 最 低 1.00
- 昨 收 1.04
- 总市值 3145.62万
- 52周最高 3.8844
- 市盈率 静 --
- 换手率 0.55%
- 52周最低 0.7702
- 委 比 87.42%
- 总股本 3114.48万
- 历史最高 87.70
- 量 比 0.73
- 振 幅 6.13%
- 历史最低 0.7702
- 每 手 1
- 风险率 0.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Senti Biosciences Q1 EPS $(0.14) Beats $(0.36) Estimate, Sales $16.000K
Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.36) by 61.11 percent. This is a 90.07 percent increase over losses of $(1.41) per share from
05-14 20:46
Senti Biosciences Announces Completion Of Type B Initial Comprehensive Multidisciplinary RMAT Meeting With FDA Regarding SENTI-202, Logic Gated Off-The-Shelf CAR-NK Cell Therapy For R/R AML And Updated Phase 1 Clinical Data
Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable
05-14 20:43
Senti Biosciences Enters Up To $40M Convertible Note Financing Agreement With Celadon Affiliate
Securities Purchase Agreement On April 27, 2026, Senti Biosciences Holdings, Inc. (the "Company"), Senti Holdings, Inc., a direct, wholly owned subsidiary of the Company ("Senti Holdings"), and Senti Biosciences,
05-02 04:11
美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $11
Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and lowers the price target from $13 to $11.
03-30 19:58
Senti Biosciences Q4 EPS $(0.53) Misses $(0.48) Estimate, Sales $22.000K Miss $666.667K Estimate
Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.48) by 11.11 percent. This is a 20.9 percent increase over losses of $(0.67) per share
03-27 20:19
Senti Biosciences Completes Enrollment In Phase 1 Clinical Trial Evaluating SENTI-202, CD33/FLT3-Targeting Logic Gated CAR NK Cell Therapy, In Patients With R/R AML
Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety profileCompany planning for rapid advancement of SENTI-202 into R/R AML pivotal
02-11 21:39
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
Market-Moving News for December 9th
XCUR: 176% | Exicure shares are trading higher after the company announced results from its completed Phase 2 trial evaluating burixafor combination with propranolol and granulocyte colony-stimulating factor for the
2025-12-09 20:21
Senti Biosciences Says FDA Grants Regenerative Medicine Advanced Therapy Designation To SENTI-202 For Treatment Of R/R Hematologic Malignancies, Including AML
RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) based on preliminary clinical evidence, and offers
2025-12-09 20:17
